Targeting LSS as A Drug Or Biomarker (G4047)

Target Name: LSS

NCBI ID: G4047

Content of Review Report on LSS Target / Biomarker

LSS

Targeting LSS as A Drug Or Biomarker

LSS (Squalene 2,3-epoxide:lanosterol cyclase) is a protein that is expressed in various tissues in the body, including the liver, heart, and kidneys. It is a key enzyme in the metabolism of lanosterol, which is a natural compound found in the body. Lanosterol is derived from cholesterol, and it has important roles in various biological processes, including the production of hormones and the regulation of inflammation.

Recent studies have suggested that LSS may be a drug target or biomarker for various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. This is because LSS is involved in the metabolism of many different compounds, and alterations in its expression or activity can have a significant impact on the health of the body.

One of the potential benefits of targeting LSS as a drug or biomarker is that it can be used to treat conditions that are currently difficult to treat or that have limited effective treatments. For example, LSS has been shown to be involved in the regulation of hormone production and has been linked to the development of various diseases, including cardiovascular disease and diabetes. By targeting LSS, researchers may be able to develop new treatments that can improve the health of patients with these conditions.

Another potential benefit of targeting LSS is that it may be a more specific and efficient target than some other potential drug targets. Because LSS is involved in a wide range of biological processes, it may be difficult to identify and target specific compounds that can effectively treat LSS-related diseases. By focusing on LSS itself, researchers may be able to develop more targeted and effective treatments.

In addition to its potential as a drug or biomarker, LSS is also of interest as a potential therapeutic target for several other conditions. For example, LSS has been shown to be involved in the regulation of cell signaling pathways that are important for many different diseases, including neurodegenerative disorders and cancer. By targeting LSS in these ways, researchers may be able to develop new treatments that can improve the health of patients with these conditions.

Overall, LSS is a protein that is expressed in various tissues in the body and is involved in the metabolism of lanosterol. Recent studies have suggested that LSS may be a drug target or biomarker for various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. By targeting LSS in these ways, researchers may be able to develop new treatments that can improve the health of patients with these conditions.

Protein Name: Lanosterol Synthase

Functions: Key enzyme in the cholesterol biosynthesis pathway. Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus (PubMed:14766201, PubMed:7639730, PubMed:26200341). Through the production of lanosterol may regulate lens protein aggregation and increase transparency (PubMed:26200341)

The "LSS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LSS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets